StreetInsider.com News Articles

Form 6-K TRINITY BIOTECH PLC For: Aug 28

Fri, 28 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260828/26999156.html

Form 6-K TRINITY BIOTECH PLC For: Aug 28

Fri, 28 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260828/26999156.html

Trinity Biotech faces Nasdaq delisting risk over market value

Fri, 28 Aug 2026 17:19:43 -0400

Trinity Biotech plc (NASDAQ: TRIB) received a staff determination letter from Nasdaq on Aug. 28, 2026, notifying the company that it failed to regain compliance with the minimum $15 million market value of publicly held shares requirement by the Aug. 18, 2026 deadline.

The company originally received a deficiency notice from Nasdaq's Listing Qualifications Department on Feb. 19, 2026, and was given 180 calendar days to comply. Having missed that deadline, Trinity Biotech's securities are subject to suspension or delisting unless the company requests a hearing before a Nasdaq Hearings Panel, which it said it intends to do. A hearing request

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

Fri, 28 Aug 2026 17:15:00 -0400

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress

- PrePsia™ patent portfolio expands to nine granted U.S. and European patents

- Company issues update on Nasdaq listing

DUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today provided an update on key developments across its diagnostics business, highlighting continued commercial progress, operational transformation and diagnostic pipeline advancement.

Strengthening Commercial Leadership in Europe

Trinity Biotech

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

Fri, 28 Aug 2026 17:15:00 -0400

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress

- PrePsia™ patent portfolio expands to nine granted U.S. and European patents

- Company issues update on Nasdaq listing

Strengthening Commercial Leadership in Europe

Trinity Biotech

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

Fri, 28 Aug 2026 17:15:00 -0400

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress

- PrePsia™ patent portfolio expands to nine granted U.S. and European patents

- Company issues update on Nasdaq listing

Strengthening Commercial Leadership in Europe

Trinity Biotech

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

Fri, 28 Aug 2026 17:15:00 -0400

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress

- PrePsia™ patent portfolio expands to nine granted U.S. and European patents

- Company issues update on Nasdaq listing

Strengthening Commercial Leadership in Europe

Trinity Biotech

Form POS AM TRINITY BIOTECH PLC

Fri, 28 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260828/26998251.html

Form POS AM TRINITY BIOTECH PLC

Fri, 28 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260828/26998251.html

Form AW TRINITY BIOTECH PLC

Thu, 27 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260827/26990693.html

Form AW TRINITY BIOTECH PLC

Thu, 27 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260827/26990693.html

Form F-1/A TRINITY BIOTECH PLC

Fri, 21 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26960798.html

Form F-1/A TRINITY BIOTECH PLC

Fri, 21 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26960798.html

Trinity Biotech's Trinovium unit partners with Echelon Data Centres

Mon, 17 Aug 2026 08:32:47 -0400

Trinity Biotech plc (NASDAQ: TRIB) announced that its Trinovium subsidiary has agreed to enter into a strategic collaboration with Echelon Data Centres to develop liquid cooling solutions for AI and high-density computing infrastructure.

Echelon, a hyperscale data center owner and operator, has more than 700 MW of capacity under development and over 1.4 GW of secured capacity across Europe. The collaboration will focus on direct-to-chip cooling fluids, thermal management systems, and modular liquid cooling solutions for AI and high-performance computing deployments.

Trinovium is drawing on Trinity Biotech's experience in precision fluid manufacturing and analytical technologies. The subsidiary has developed an initial direct-to-chip

Form 6-K TRINITY BIOTECH PLC For: Aug 17

Mon, 17 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26935390.html

Form 6-K TRINITY BIOTECH PLC For: Aug 17

Mon, 17 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26935390.html

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

Mon, 17 Aug 2026 08:30:00 -0400

- Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooling technologies for next-generation AI and modular data center infrastructure

- Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033¹

DUBLIN and WILSONVILLE, Ore., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) today announced that Trinovium, a subsidiary focused on advanced liquid cooling solutions and fluid intelligence systems for next-generation AI data centers, has agreed to enter into a strategic collaboration agreement with

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

Mon, 17 Aug 2026 08:30:00 -0400

- Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033¹

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

Mon, 17 Aug 2026 08:30:00 -0400

- Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033¹

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

Mon, 17 Aug 2026 08:30:00 -0400

- Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033¹

Form 6-K TRINITY BIOTECH PLC For: Aug 14

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926151.html

Form 6-K TRINITY BIOTECH PLC For: Aug 14

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926151.html

Trinity Biotech secures $7M from Perceptive, regains Nasdaq compliance

Fri, 14 Aug 2026 09:33:13 -0400

Trinity Biotech plc (NASDAQ: TRIB) announced it has received $7.0 million in additional investment from funds managed by Perceptive Advisors and has regained compliance with Nasdaq's minimum bid price requirement, according to a press release.

The $7.0 million investment comprises approximately $2.5 million in new debt funding and approximately $4.5 million of capitalized interest under an amendment to the company's existing financing arrangements. Perceptive Advisors is described as Trinity Biotech's largest financial investor and primary lender.

On August 7, 2026, Trinity Biotech received confirmation from The Nasdaq Stock Market LLC that it had regained compliance with the minimum bid price requirement under

Trinity Biotech secures $7M from Perceptive, regains Nasdaq compliance

Fri, 14 Aug 2026 09:33:13 -0400

On August 7, 2026, Trinity Biotech received confirmation from The Nasdaq Stock Market LLC that it had regained compliance with the minimum bid price requirement under

Trinity Biotech secures $7M from Perceptive, regains Nasdaq compliance

Fri, 14 Aug 2026 09:33:13 -0400

On August 7, 2026, Trinity Biotech received confirmation from The Nasdaq Stock Market LLC that it had regained compliance with the minimum bid price requirement under